Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia

Sebastian R Hobson, Seshini Gurusinghe, Rebecca Lim, Nicole O Alers, Suzanne L Miller, John C Kingdom, Euan M Wallace

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)

Abstract

Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. There have been no material advances in the treatment of preeclampsia for nearly 50 years. Combining in vitro studies and a clinical trial, we aimed to determine whether melatonin could be a useful adjuvant therapy. In a xanthine/xanthine oxidase (X/XO) placental explant model, melatonin reduced oxidative stress (8-isoprostane) and enhanced antioxidant markers (Nrf2 translocation, HO-1), but did not affect explant production of anti-angiogenic factors (sFlt, sEng, activin A). In cultured HUVECs, melatonin mitigated TNFα-induced vascular cell adhesion molecule expression and rescued the subsequent disruption to endothelial monolayer integrity but did not affect other markers for endothelial activation and dysfunction. In a phase I trial of melatonin in 20 women with preeclampsia, we assessed the safety and efficacy of melatonin on (i) preeclampsia progression, (ii) clinical outcomes, and (iii) oxidative stress, matching outcomes with recent historical controls receiving similar care. Melatonin therapy was safe for mothers and their fetuses. Compared to controls, melatonin administration extended the mean ± SEM diagnosis to delivery interval by 6 ± 2.3 days reduced the need for increasing antihypertensive medication on days 3-4 (13% vs 71%), days 6-7 (8% vs 51%), and at delivery (26% vs 75%). All other clinical and biochemical measures of disease severity were unaffected by melatonin. We have shown that melatonin has the potential to mitigate maternal endothelial pro-oxidant injury and could therefore provide effective adjuvant therapy to extend pregnancy duration to deliver improved clinical outcomes for women with severe preeclampsia.

Original languageEnglish
Article numbere12508
Number of pages14
JournalJournal of Pineal Research
Volume65
Issue number3
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • endothelial cell
  • hypertension
  • melatonin
  • placenta
  • preeclampsia
  • pregnancy

Cite this

@article{f2ff08a249b74b9d86ad28a74ee9a235,
title = "Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia",
abstract = "Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. There have been no material advances in the treatment of preeclampsia for nearly 50 years. Combining in vitro studies and a clinical trial, we aimed to determine whether melatonin could be a useful adjuvant therapy. In a xanthine/xanthine oxidase (X/XO) placental explant model, melatonin reduced oxidative stress (8-isoprostane) and enhanced antioxidant markers (Nrf2 translocation, HO-1), but did not affect explant production of anti-angiogenic factors (sFlt, sEng, activin A). In cultured HUVECs, melatonin mitigated TNFα-induced vascular cell adhesion molecule expression and rescued the subsequent disruption to endothelial monolayer integrity but did not affect other markers for endothelial activation and dysfunction. In a phase I trial of melatonin in 20 women with preeclampsia, we assessed the safety and efficacy of melatonin on (i) preeclampsia progression, (ii) clinical outcomes, and (iii) oxidative stress, matching outcomes with recent historical controls receiving similar care. Melatonin therapy was safe for mothers and their fetuses. Compared to controls, melatonin administration extended the mean ± SEM diagnosis to delivery interval by 6 ± 2.3 days reduced the need for increasing antihypertensive medication on days 3-4 (13{\%} vs 71{\%}), days 6-7 (8{\%} vs 51{\%}), and at delivery (26{\%} vs 75{\%}). All other clinical and biochemical measures of disease severity were unaffected by melatonin. We have shown that melatonin has the potential to mitigate maternal endothelial pro-oxidant injury and could therefore provide effective adjuvant therapy to extend pregnancy duration to deliver improved clinical outcomes for women with severe preeclampsia.",
keywords = "endothelial cell, hypertension, melatonin, placenta, preeclampsia, pregnancy",
author = "Hobson, {Sebastian R} and Seshini Gurusinghe and Rebecca Lim and Alers, {Nicole O} and Miller, {Suzanne L} and Kingdom, {John C} and Wallace, {Euan M}",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/jpi.12508",
language = "English",
volume = "65",
journal = "Journal of Pineal Research",
issn = "0742-3098",
publisher = "Wiley-Blackwell",
number = "3",

}

Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. / Hobson, Sebastian R; Gurusinghe, Seshini; Lim, Rebecca; Alers, Nicole O; Miller, Suzanne L; Kingdom, John C; Wallace, Euan M.

In: Journal of Pineal Research, Vol. 65, No. 3, e12508, 01.10.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia

AU - Hobson, Sebastian R

AU - Gurusinghe, Seshini

AU - Lim, Rebecca

AU - Alers, Nicole O

AU - Miller, Suzanne L

AU - Kingdom, John C

AU - Wallace, Euan M

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. There have been no material advances in the treatment of preeclampsia for nearly 50 years. Combining in vitro studies and a clinical trial, we aimed to determine whether melatonin could be a useful adjuvant therapy. In a xanthine/xanthine oxidase (X/XO) placental explant model, melatonin reduced oxidative stress (8-isoprostane) and enhanced antioxidant markers (Nrf2 translocation, HO-1), but did not affect explant production of anti-angiogenic factors (sFlt, sEng, activin A). In cultured HUVECs, melatonin mitigated TNFα-induced vascular cell adhesion molecule expression and rescued the subsequent disruption to endothelial monolayer integrity but did not affect other markers for endothelial activation and dysfunction. In a phase I trial of melatonin in 20 women with preeclampsia, we assessed the safety and efficacy of melatonin on (i) preeclampsia progression, (ii) clinical outcomes, and (iii) oxidative stress, matching outcomes with recent historical controls receiving similar care. Melatonin therapy was safe for mothers and their fetuses. Compared to controls, melatonin administration extended the mean ± SEM diagnosis to delivery interval by 6 ± 2.3 days reduced the need for increasing antihypertensive medication on days 3-4 (13% vs 71%), days 6-7 (8% vs 51%), and at delivery (26% vs 75%). All other clinical and biochemical measures of disease severity were unaffected by melatonin. We have shown that melatonin has the potential to mitigate maternal endothelial pro-oxidant injury and could therefore provide effective adjuvant therapy to extend pregnancy duration to deliver improved clinical outcomes for women with severe preeclampsia.

AB - Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. There have been no material advances in the treatment of preeclampsia for nearly 50 years. Combining in vitro studies and a clinical trial, we aimed to determine whether melatonin could be a useful adjuvant therapy. In a xanthine/xanthine oxidase (X/XO) placental explant model, melatonin reduced oxidative stress (8-isoprostane) and enhanced antioxidant markers (Nrf2 translocation, HO-1), but did not affect explant production of anti-angiogenic factors (sFlt, sEng, activin A). In cultured HUVECs, melatonin mitigated TNFα-induced vascular cell adhesion molecule expression and rescued the subsequent disruption to endothelial monolayer integrity but did not affect other markers for endothelial activation and dysfunction. In a phase I trial of melatonin in 20 women with preeclampsia, we assessed the safety and efficacy of melatonin on (i) preeclampsia progression, (ii) clinical outcomes, and (iii) oxidative stress, matching outcomes with recent historical controls receiving similar care. Melatonin therapy was safe for mothers and their fetuses. Compared to controls, melatonin administration extended the mean ± SEM diagnosis to delivery interval by 6 ± 2.3 days reduced the need for increasing antihypertensive medication on days 3-4 (13% vs 71%), days 6-7 (8% vs 51%), and at delivery (26% vs 75%). All other clinical and biochemical measures of disease severity were unaffected by melatonin. We have shown that melatonin has the potential to mitigate maternal endothelial pro-oxidant injury and could therefore provide effective adjuvant therapy to extend pregnancy duration to deliver improved clinical outcomes for women with severe preeclampsia.

KW - endothelial cell

KW - hypertension

KW - melatonin

KW - placenta

KW - preeclampsia

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85052897254&partnerID=8YFLogxK

U2 - 10.1111/jpi.12508

DO - 10.1111/jpi.12508

M3 - Article

VL - 65

JO - Journal of Pineal Research

JF - Journal of Pineal Research

SN - 0742-3098

IS - 3

M1 - e12508

ER -